Publications by authors named "Jeffrey A Cohen"

100Publications

Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder.

Mult Scler 2021 Jan 6:1352458520981736. Epub 2021 Jan 6.

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
January 2021

Long-term ocrelizumab in progressive multiple sclerosis.

Lancet Neurol 2020 12 29;19(12):966-968. Epub 2020 Oct 29.

Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44915, USA. Electronic address:

View Article and Find Full Text PDF
December 2020

Response of the multiple sclerosis community to COVID-19.

Mult Scler 2020 09;26(10):1134-1136

Mellen Center (J.A.C.), Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
September 2020

Long-term prognostic value of longitudinal measurements of blood neurofilament levels.

Neurol Neuroimmunol Neuroinflamm 2020 09 12;7(5). Epub 2020 Aug 12.

From the Novartis Pharma AG (D.A.H., H.K., D.T.), Basel; Research Center for Clinical Neuroimmunology and Neuroscience Basel (L.K., D.L., J.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Switzerland; Department of Neurology (J.A.C.), Mellen MS Center, Neurological Institute, Cleveland Clinic, OH; Novartis Healthcare Pvt. Ltd. (A.S.), Hyderabad, India; and DATAMAP GmbH (R.M.), Freiburg, Germany.

View Article and Find Full Text PDF
September 2020

The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis.

Neurotherapeutics 2020 07;17(3):968-970

Mellen Center U-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH, 44195, USA.

View Article and Find Full Text PDF
July 2020

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

N Engl J Med 2020 08;383(6):546-557

From the UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco (S.L.H.); the Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.B.-O.); the Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland (J.A.C.); the Institute of Experimental Neurology and Multiple Sclerosis Center IRCCS, San Raffaele Hospital, Milan (G.C.); the Department of Neurology, Fleni, Buenos Aires (J.C.); the Department of Neurology, Stony Brook University, Stony Brook, NY (P.K.C.); Washington University School of Medicine, St. Louis (A.H.C.); the University Hospital of Strasburg and Clinical Investigation Center INSERM 1434, Strasburg, France (J.S.); University Hospital Basel (D.L.), Novartis Pharma (C.K., R.W., A.K., D.T., D.A.H., K.R., M.M.), and the Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel (L.K.) - all in Basel, Switzerland; the Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona (X.M.); the University of Warmia and Mazury, Olsztyn, and the Center of Neurology, Lodz - both in Poland (K.S.); the Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany (H.W.); and Novartis Pharmaceuticals, East Hanover, NJ (B.L., A.G., R.P.).

View Article and Find Full Text PDF
August 2020

Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Neurol Clin Pract 2020 Jun;10(3):222-231

Mellen Center for Multiple Sclerosis (GM, BPM, LEB, MW, MA, FB, AB, DC, DSC, CF, RJF, SG, BG, CH-C, KRM, MPM, DMM, MN, AR-G, MR, HY, MAW, DO, JAC, RAB), Neurological Institute, Cleveland Clinic Foundation; Department of Quantitative Health Sciences (HL), Cleveland Clinic; Schey Center for Cognitive Neuroimaging (SMR), Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic Foundation; Department of Biomedical Engineering (DS, JLA), Lerner Research Institute, Cleveland Clinic Foundation, OH; and Epic Systems Corporation (NJ), Verona, WI.

View Article and Find Full Text PDF
June 2020

Keep the Worms in the Mud.

JAMA Neurol 2020 Sep;77(9):1066-1067

Mellen Center for Multiple Sclerosis, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.

View Article and Find Full Text PDF
September 2020

The 2013 clinical course descriptors for multiple sclerosis: A clarification.

Neurology 2020 06 29;94(24):1088-1092. Epub 2020 May 29.

From the Department of Neurology (F.D.L.), Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY; National Multiple Sclerosis Society (T.C.), New York, NY; Department of Neurology (J.A.C.), Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, OH; Departments of Internal Medicine (Neurology) and Community Health Sciences (R.A.M.), Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada; and Faculty of Brain Sciences (A.J.T.), University College, London, United Kingdom.

View Article and Find Full Text PDF
June 2020

Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.

Ann Neurol 2020 07 1;88(1):81-92. Epub 2020 May 1.

Mellen Center for MS Treatment and Research, Neurologic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

View Article and Find Full Text PDF
July 2020

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Lancet Neurol 2020 04 11;19(4):336-347. Epub 2020 Feb 11.

Neurology Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedicine University Hospital Basel, University of Basel, Basel, Switzerland; Department of Biomedical Engineering, University Hospital Basel, University of Basel, Basel, Switzerland.

View Article and Find Full Text PDF
April 2020

MSJ 2020 - Editorial comment.

Mult Scler 2020 02;26(2):134

VU University Medical Centre, Amsterdam, The Netherlands.

View Article and Find Full Text PDF
February 2020

Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder.

Neurology 2020 02 31;94(6):273-275. Epub 2019 Dec 31.

From the Mellen Center for Multiple Sclerosis Treatment and Research (G.M., M.A.W., D.O., J.A.C.), Neurological Institute, Cleveland Clinic; Center for Neurorestoration (H.F.), Neurological Institute, Cleveland Clinic; Neuroradiology Department (S.K., S.E.J.), Imaging Institute, Cleveland Clinic; and Neuromuscular Center (E.P.P.), Neurological Institute, Cleveland Clinic, OH.

View Article and Find Full Text PDF
February 2020

Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero.

Mult Scler J Exp Transl Clin 2019 Oct-Dec;5(4):2055217319891744. Epub 2019 Dec 12.

Mellen Center for MS Treatment and Research, Cleveland Clinic, United States of America.

View Article and Find Full Text PDF
December 2019

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.

Mult Scler 2020 01 28;26(1):23-37. Epub 2019 Nov 28.

Departments of Internal Medicine (Neurology) and Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.

View Article and Find Full Text PDF
January 2020

Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation.

Mult Scler J Exp Transl Clin 2019 Oct-Dec;5(4):2055217319887198. Epub 2019 Nov 5.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, USA.

View Article and Find Full Text PDF
November 2019

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.

Neurology 2019 11 22;93(21):e1921-e1931. Epub 2019 Oct 22.

From the University of Virginia (M.D.G.), Charlottesville; National Multiple Sclerosis Society (N.G.L.), New York, NY; Biogen (R.A.R., G.P.), Cambridge, MA; Critical Path Institute (L.D.H.), Tucson, AZ; Genentech (P.S.C.), South San Francisco, CA; Independent Neurology Clinical Development Consultant (G.S.F.); Premier Research (A.J.), Wokingham, UK; UCL Institute of Neurology (R.K.), London, UK; Imperial College London and UK Dementia Research Institute (P.M.M.); Johns Hopkins (E.M.M.), Baltimore, MD; New York University School of Medicine (L.J.B.), NY; Wave Life Sciences (M.P.), Cambridge, MA; VU University Medical Center (B.M.J.U.), Amsterdam, the Netherlands; and Cleveland Clinic (J.A.C.), OH.

View Article and Find Full Text PDF
November 2019

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results.

Ther Adv Neurol Disord 2019 25;12:1756286419878324. Epub 2019 Sep 25.

Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland.

View Article and Find Full Text PDF
September 2019

Complex intensive treatment shows promise against a complex aggressive disease.

Neurology 2019 10 2;93(18):776-777. Epub 2019 Oct 2.

From the Department of Brain Sciences (P.A.M.), Imperial College London, UK; and Neurological Institute (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
October 2019

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.

Neurol Neuroimmunol Neuroinflamm 2019 11 11;6(6). Epub 2019 Sep 11.

From the Central Texas Neurology Consultants (E.J.F.), Round Rock, TX; Icahn School of Medicine at Mount Sinai (F.D.L.), New York, NY; McGovern Medical School (J.S.W.), The University of Texas Health Science Center at Houston (UTHealth), TX; Mellen Center for Multiple Sclerosis Treatment and Research (J.A.C.), Neurological Institute, Cleveland Clinic Foundation, OH; Oxford PharmaGenesis Ltd (I.M.W.), UK; Novartis Pharmaceuticals Corporation (X.M., M.Z., S.K.), East Hanover, NJ; and The University of California, San Francisco (UCSF); Weill Institute for Neurosciences, Department of Neurology (B.A.C.C.), San Francisco, CA.

View Article and Find Full Text PDF
November 2019

Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.

Mult Scler 2020 10 1;26(12):1581-1589. Epub 2019 Aug 1.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
October 2020

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Neurol Neuroimmunol Neuroinflamm 2019 09 28;6(5):e583. Epub 2019 Jun 28.

University of Utah School of Medicine (L.J.C., J.W.R., J.S.A., A.M.J., R.K., B.M., M.P., R.E., J.Y., S.M.), Salt Lake City; Division of Neuroimmunology and Multiple Sclerosis Center (M.H.H.), Department of Neurology and Neurological Sciences, Stanford University; Department of Neurology and Neurological Sciences (A.J.T.), Stanford School of Medicine, CA; Department of Neurology, Johns Hopkins University School of Medicine (M.L., M.A.M., J.C.), Baltimore, MD; Departments of Neurology and Ophthalmology (J.L.B., R.J., M.B.-G.), University of Colorado School of Medicine, Aurora; Department of Medicine & Neurology (A.L.T., R.L.C., L.E.L., J.J.S., K.M.), University of British Columbia, Vancouver, Canada; NYU Langone Health (I.K., Z.R., A.R.), New York; Department of Neurology, Cedars-Sinai Medical Center (N.L.S.), Los Angeles, CA; Mellen Center for MS Treatment and Research (S.M.P., J.A.C., D.I., J.L.S.), Neurological Institute, Cleveland Clinic, OH; Icahn School of Medicine at Mount Sinai (I.K.S.), New York; Multiple Sclerosis Center (P.R.), Swedish Neuroscience Institute, Seattle, WA; Department of Neurology (L.A., A.P., E.A.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Neurology (T.C., D.S.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology (E.C.K., A.W.R.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology (C.S.R., K.B.O., L.L., K.E.N.), Columbia University Medical Center; Weill Cornell Medicine (M.M.N., C.E., M.K.-H., M.M.), New York; Department of Neurology (L.T.), Division of Multiple Sclerosis, University of Miami Miller School of Medicine, FL; PPD (A.R., A.G.), Wilmington, NC; The Guthy-Jackson Charitable Foundation (M.K.B., R.R.R., D.W. Behne., D.W. Blackway, B.C., J.S., J.M.B.), Beverly Hills; Departments of Medicine and of Molecular Pharmacology (T.F.B.), Stanford University School of Medicine, CA; Kellogg Eye Center (T.J.S.), University of Michigan Medical School, Ann Arbor; Department of Medicine, University of California, Los Angeles (M.R.Y.); and Harbor-UCLA Medical Center/LABioMed (M.R.Y.), Torrance, CA.

View Article and Find Full Text PDF
September 2019

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Mult Scler J Exp Transl Clin 2019 Apr-Jun;5(2):2055217319856035. Epub 2019 Jun 14.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, USA.

View Article and Find Full Text PDF
June 2019

Developing therapeutic strategies to promote myelin repair in multiple sclerosis.

Expert Rev Neurother 2019 10 20;19(10):997-1013. Epub 2019 Jun 20.

Mellen Center for MS Treatment and Research, Cleveland Clinic , Cleveland , OH , USA.

View Article and Find Full Text PDF
October 2019

The emergence of follow-on disease-modifying therapies for multiple sclerosis.

Mult Scler 2019 10 10;25(12):1560-1565. Epub 2019 May 10.

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
October 2019

Movement disorders in early MS and related diseases: A prospective observational study.

Neurol Clin Pract 2019 Feb;9(1):24-31

Multiple Sclerosis and Neuroimmunology Program (HA), University Hospitals of Cleveland; Case Western Reserve University School of Medicine (HA, KK), Cleveland; and Center for Neurological Restoration (XXY, HHF) and The Mellen Center for Multiple Sclerosis Treatment and Research (JAC), Cleveland Clinic, OH.

View Article and Find Full Text PDF
February 2019

Follow-on glatiramer acetate.

eNeurologicalSci 2018 Dec 23;13:51-52. Epub 2018 Nov 23.

Synthon BV, Nijmegen, The Netherlands.

View Article and Find Full Text PDF
December 2018

Genetic findings in adolescent and adult-onset leukodystrophies with hypomyelinating features.

J Neurol Neurosurg Psychiatry 2019 Jul 2;90(7):836-838. Epub 2018 Nov 2.

Department of Neurology, Reference Center for Lysosomal Diseases, Neuro-Genetic and Metabolism, Groupe Hospitalier Pitié-Salpêtrière (AP-HP), Paris, France

View Article and Find Full Text PDF
July 2019

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Neurol Clin Pract 2018 Aug;8(4):292-301

Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus (BV, KN, SS, JRC, TV, EA), University of Colorado, Denver; Mellen Center for Multiple Sclerosis Treatment and Research (DO, RAB, RJF, JAC), Cleveland Clinic, OH; Emory University (AB), Atlanta, GA; Department of Neurology (SC), Cleveland Clinic, OH; and Lou Ruvo Center for Brain Health (CMH), Cleveland Clinic, Las Vegas, NV.

View Article and Find Full Text PDF
August 2018

Integrating multiple sclerosis guidelines into practice.

Lancet Neurol 2018 08 17;17(8):658-660. Epub 2018 Jul 17.

Neurologic Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address:

View Article and Find Full Text PDF
August 2018

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply.

Lancet Neurol 2018 06;17(6):499-500

Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

View Article and Find Full Text PDF
June 2018

Neuromuscular diseases associated with Human Immunodeficiency Virus infection.

J Neurol Sci 2018 04 31;387:27-36. Epub 2018 Jan 31.

Dartmouth Hitchcock Medical Center, Department of Neurology, 1 Medical Center Drive, Lebanon, NH 03756, United States. Electronic address:

View Article and Find Full Text PDF
April 2018

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.

EBioMedicine 2018 03 23;29:5-6. Epub 2018 Feb 23.

Mellen Center for Multiple Sclerosis Research and Treatment, Neurological Institute, Cleveland Clinic. Electronic address:

View Article and Find Full Text PDF
March 2018

Comorbidities in MS are associated with treatment intolerance and disability.

Neurology 2017 11 1;89(22):2218-2219. Epub 2017 Nov 1.

From the MS Clinic (G.V.M.), Belfast City Hospital, Northern Ireland, UK; and Neurological Institute (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
November 2017

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Ther Clin Risk Manag 2017 16;13:1423-1437. Epub 2017 Oct 16.

Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.

View Article and Find Full Text PDF
October 2017

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mult Scler Relat Disord 2017 Oct 22;17:12-14. Epub 2017 Jun 22.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
October 2017

Cell-based therapeutic strategies for multiple sclerosis.

Brain 2017 11;140(11):2776-2796

Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
November 2017

Clinical outcome measures for progressive MS trials.

Mult Scler 2017 Oct;23(12):1627-1635

Department NEUROFARBA, Section Neurosciences, University of Florence, Florence, Italy.

View Article and Find Full Text PDF
October 2017

Clemastine fumarate for promotion of optic nerve remyelination.

Lancet 2017 12 10;390(10111):2421-2422. Epub 2017 Oct 10.

Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

View Article and Find Full Text PDF
December 2017

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Neurotherapeutics 2017 10;14(4):832-834

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA.

View Article and Find Full Text PDF
October 2017

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Mult Scler J Exp Transl Clin 2017 Jul-Sep;3(3):2055217317715485. Epub 2017 Aug 24.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, USA.

View Article and Find Full Text PDF
August 2017

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Neurology 2017 Sep 23;89(11):1117-1126. Epub 2017 Aug 23.

From the Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General Hospital in Prague, Czech Republic; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology (S.S.), University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Sanofi (D.H.M., K.T., M.C.C., D.J., M.A.P.), Cambridge, MA; Envision Scientific Solutions (P.X.), Philadelphia, PA; Envision Scientific Solutions (R.J.H.), Sydney, NSW, Australia; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article and Find Full Text PDF
September 2017

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Neurology 2017 Sep 23;89(11):1107-1116. Epub 2017 Aug 23.

From the Department of Neurology and Center for Clinical Neuroscience (E.H.), First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; NeuroRx Research (D.L.A.), Montréal; Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; MS Clinic of Central Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zürich and University of Zürich, Switzerland; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; The University of British Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.

View Article and Find Full Text PDF
September 2017

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Neurotherapeutics 2017 Oct;14(4):859-873

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue/U10, Cleveland, OH, 44195, USA.

View Article and Find Full Text PDF
October 2017

Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Neurotherapeutics 2017 Oct;14(4):952-960

Lou Ruvo Center for Brain Health, Cleveland Clinic, 888 W. Bonneville, Las Vegas, NV, USA.

View Article and Find Full Text PDF
October 2017

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Mult Scler 2018 04 6;24(4):501-511. Epub 2017 Apr 6.

Case Comprehensive Cancer Center and National Center for Regenerative Medicine, Case Western Reserve University and Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

View Article and Find Full Text PDF
April 2018

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Mult Scler 2017 Apr 16;23(5):704-710. Epub 2017 Feb 16.

Multiple Sclerosis Outcome Assessments Consortium (MSOAC), Critical Path Institute, Tucson, AZ, USA.

View Article and Find Full Text PDF
April 2017

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

Mult Scler 2017 Dec 16;23(14):1909-1917. Epub 2017 Jan 16.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
December 2017

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Mult Scler Relat Disord 2016 Nov 8;10:44-52. Epub 2016 Aug 8.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, 44195 USA.

View Article and Find Full Text PDF
November 2016

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Lancet 2017 04 24;389(10076):1357-1366. Epub 2016 Nov 24.

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:

View Article and Find Full Text PDF
April 2017

Safety of monoclonal antibodies for the treatment of multiple sclerosis.

Expert Opin Drug Saf 2017 Jan 31;16(1):89-100. Epub 2016 Oct 31.

a Mellen Center for Multiple Sclerosis Treatment and Research , Neurological Institute, Cleveland Clinic , Cleveland , OH , USA.

View Article and Find Full Text PDF
January 2017

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Neurology 2016 Nov 12;87(19):1985-1992. Epub 2016 Oct 12.

From Queen Mary University of London (G.G.), Barts and The London School of Medicine, UK; Mellen Center (J.A.C.), Cleveland Clinic, OH; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology and Center for Clinical Neuroscience (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Sanofi Genzyme (D.H.M., S.L.L., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (S.M.K.), Philadelphia, PA (at the time the work was conducted).

View Article and Find Full Text PDF
November 2016

Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

Mult Scler Relat Disord 2016 Sep 27;9:129-34. Epub 2016 Jul 27.

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundatio, 9500 Euclid Avenue/U10, Cleveland, OH, 44195 USA.

View Article and Find Full Text PDF
September 2016

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Neurology 2016 Oct 2;87(14):1464-1472. Epub 2016 Sep 2.

From NeuroRx Research (D.L.A.) and Department of Neurology and Neurosurgery (D.L.A.), Montréal Neurological Institute, McGill University, Québec, Canada; Department of Biomedical Engineering (E.F.) and Mellen Center (J.A.C.), Cleveland Clinic, OH; Zagreb Medical School and University Hospital Center (V.V.B.), Croatia; Department of Clinical Neurosciences (A.J.C., D.A.S.C.), University of Cambridge, UK; Queen Mary University of London (G.G.), Barts and the London School of Medicine, UK; Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Heinrich-Heine University, Düsseldorf, Germany; Department of Neurology (E.H.), First Medical Faculty, Charles University in Prague, Czech Republic; Department of Neurology (K.W.S.), Medical University of Łódź, Poland; Clinical Centre Kragujevac (M.S.), Clinic of Neurology, Serbia; Brigham and Women's Hospital Center for Neurologic Diseases (H.L.W.), Boston, MA; Sanofi Genzyme (S.L.L., D.H.M., M.A.P.), Cambridge, MA; and Evidence Scientific Solutions (D.R.T.), Horsham, West Sussex, UK. Dr. Panzara is currently with Wave Life Sciences, Cambridge, MA.

View Article and Find Full Text PDF
October 2016

Considerations in the development of generic disease therapies for multiple sclerosis.

Neurol Clin Pract 2016 Aug;6(4):369-376

Lou Ruvo Center for Brain Health (LHH), Cleveland Clinic, Las Vegas, NV; and Mellen Center for Multiple Sclerosis Treatment and Research (JAC), Cleveland Clinic, Cleveland, OH.

View Article and Find Full Text PDF
August 2016

Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.

Mult Scler 2017 Feb 11;23(2):277-285. Epub 2016 Jul 11.

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

View Article and Find Full Text PDF
February 2017

Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.

Nat Rev Neurol 2016 05 29;12(5):253-4. Epub 2016 Mar 29.

Mellen Center for Multiple Sclerosis Treatment and Research in the Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44915, USA.

View Article and Find Full Text PDF
May 2016

The challenge of comorbidity in clinical trials for multiple sclerosis.

Neurology 2016 Apr 17;86(15):1437-1445. Epub 2016 Feb 17.

From the Departments of Internal Medicine (R.A.M.) and Community Health Sciences (R.A.M.), University of Manitoba, Winnipeg, Canada; Icahn School of Medicine at Mount Sinai (A.M.), New York, NY; Biostatistic Unit (M.P.S.), Department of Health Sciences, University of Genova, Italy; Faculty of Brain Sciences (A.T.), University College London, UK; University of California San Francisco (E.W.); Department of Basic Medical Sciences, Neurosciences and Sense Organs (M.T.), University of Bari, Italy; St. Michael's Hospital (P.O.), Toronto, Canada; Scientific and Clinical Review Associates, LLC (S.R.), Salisbury, CT; and Mellen Center for MS Treatment and Research (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
April 2016

Recommendations for observational studies of comorbidity in multiple sclerosis.

Neurology 2016 Apr 10;86(15):1446-1453. Epub 2016 Feb 10.

From the Departments of Internal Medicine (R.A.M., K.F.) and Community Health Sciences (R.A.M., N.R.), University of Manitoba, Winnipeg, Canada; Icahn School of Medicine at Mount Sinai (A.M.), New York, NY; Biostatistic Unit, Department of Health Sciences (M.P.S.), University of Genova, Italy; Faculty of Brain Sciences (A.T.), University College London, UK; University of California San Francisco (E.W.); Department of Basic Medical Sciences, Neurosciences and Sense Organs (M.T.), University of Bari, Italy; St. Michael's Hospital (P.O.), Toronto, Canada; Scientific and Clinical Review Associates, LLC (S.R.), Salisbury, CT; and Mellen Center for MS Treatment and Research (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
April 2016

Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?

Expert Rev Clin Immunol 2016 19;12(5):489-91. Epub 2016 Feb 19.

a Mellen Center for Multiple Sclerosis Treatment and Research , Neurological Institute, Cleveland Clinic , Cleveland , OH , USA.

View Article and Find Full Text PDF
January 2017

The first volume of MSJ-ETC.

Mult Scler J Exp Transl Clin 2016 Jan-Dec;2:2055217315626042. Epub 2016 Jan 22.

Hospital Universitari Vall d'Hebron, Spain.

View Article and Find Full Text PDF
January 2016

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

Authors:
Ted M Burns Gordon A Smith Jeffrey A Allen Anthony A Amato W David Arnold Richard Barohn Michael Benatar Shawn J Bird Mark Bromberg Nizar Chahin Emma Ciafaloni Jeffrey A Cohen Andrea Corse Brian A Crum William S David Elliot Dimberg Eduardo A De Sousa Peter D Donofrio P James B Dyck Andrew G Engel Erik R Ensrud Mark Ferrante Miriam Freimer Karissa L Gable Summer Gibson James M Gilchrist Jonathan M Goldstein Clifton L Gooch Brent P Goodman Dmitri Gorelov Sidney M Gospe Namita A Goyal Amanda C Guidon Jeffrey T Guptill Laurie Gutmann Ludwig Gutmann Kelly Gwathmey Yadollah Harati C Michel Harper Michael K Hehir Lisa D Hobson-Webb James F Howard Carlayne E Jackson Nicholas Johnson Sarah M Jones Vern C Juel Henry J Kaminski Chafic Karam Kathleen D Kennelly Sami Khella Julie Khoury John C Kincaid John T Kissel Noah Kolb David Lacomis Shafeeq Ladha Daniel Larriviere Richard A Lewis Yuebing Li William J Litchy Eric Logigian Jau-Shin Lou Daniel J L MacGowen Ricardo Maselli Janice M Massey Michelle L Mauermann Katherine D Mathews Matthew N Meriggioli Robert G Miller Joon-Shik Moon Tahseen Mozaffar Sharon P Nations Richard J Nowak Lyle W Ostrow Robert M Pascuzzi Amanda Peltier Katherine Ruzhansky David P Richman Mark A Ross Devon I Rubin James A Russell George M Sachs Mohammad Kian Salajegheh David S Saperstein Stephen Scelsa Duygu Selcen Aziz Shaibani Perry B Shieh Nicholas J Silvestri J Rob Singleton Benn E Smith Yuen T So Guillermo Solorzano Eric J Sorenson Jayashri Srinivasen Jinny Tavee Rabi Tawil Pariwat Thaisetthawatkul Charles Thornton Jaya Trivedi Steven Vernino Annabel K Wang Tyler A Webb Michael D Weiss Anthony J Windebank Gil I Wolfe

Muscle Nerve 2016 Feb 21;53(2):165-8. Epub 2015 Dec 21.

Department of Neurology, University of Buffalo, Buffalo, New York, USA.

View Article and Find Full Text PDF
February 2016

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

Mult Scler Relat Disord 2014 Sep 17;3(5):629-38. Epub 2014 Jun 17.

Neurology, Departments of Medicine, Clinical Research and Biomedicine, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. Electronic address:

View Article and Find Full Text PDF
September 2014

Sphingosine 1-phosphate receptor modulators in multiple sclerosis.

CNS Drugs 2015 Jul;29(7):565-75

Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue/U10, Cleveland, OH, 44195, USA,

View Article and Find Full Text PDF
July 2015

Cause, effect and consequence? Painful small fiber sensory polyneuropathy and impaired glycemia.

J Neurol Sci 2015 Aug 27;355(1-2):1-2. Epub 2015 May 27.

Department of Neurology Geisel School of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States.

View Article and Find Full Text PDF
August 2015

Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.

Nat Rev Neurol 2015 Jun 21;11(6):316-7. Epub 2015 Apr 21.

Mellen Center for MS Treatment and Research, Neurological institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
June 2015

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.

Case Rep Neurol Med 2015 29;2015:892047. Epub 2015 Jan 29.

Department of Neurology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03766, USA.

View Article and Find Full Text PDF
February 2015

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.

Neurology 2015 Feb 28;84(8):784-93. Epub 2015 Jan 28.

From the Medical Image Analysis Centre (E.-W.R.), University Hospital, University of Basel, Switzerland; Image Analysis Center (F.B.), VU Medical Centre, Amsterdam, the Netherlands; Departments of Medicine and Clinical Research, Neurology (L.K., T.S.) and Radiology (T.S.), Division of Neuroradiology, University Hospital, Basel, Switzerland; Novartis Pharma AG (D.A.H., A.d.V., P.v.R.), Basel, Switzerland; Oxford PharmaGenesis Ltd. (J.R.B.), Tubney, Oxford, UK; Novartis Pharmaceuticals Corporation (G.F.), East Hanover, NJ; and Neurological Institute (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
February 2015

Vision and vision-related outcome measures in multiple sclerosis.

Brain 2015 Jan 28;138(Pt 1):11-27. Epub 2014 Nov 28.

4 Neurological Institute, Cleveland Clinic, OH 44195, USA

View Article and Find Full Text PDF
January 2015

Experience with fingolimod in clinical practice.

Int J Neurosci 2015 29;125(9):678-85. Epub 2014 Oct 29.

1Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article and Find Full Text PDF
May 2016

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

JAMA Neurol 2014 Nov;71(11):1386-93

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio7currently with Biogen Idec, Weston, Massachusetts.

View Article and Find Full Text PDF
November 2014

Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.

Mult Scler 2014 Sep;20(10):1280-1

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, USA

View Article and Find Full Text PDF
September 2014

Venous angioplasty for "CCSVI" in multiple sclerosis: ending a therapeutic misadventure.

Neurology 2014 Jul 27;83(5):388-9. Epub 2014 Jun 27.

From the Department of Neurology (D.N.B.), Oregon Health & Science University and Multiple Sclerosis Center of Excellence West, Veterans Affairs Medical Center, Portland; and the Mellen Center for MS Treatment and Research (J.A.C.), Cleveland Clinic, OH.

View Article and Find Full Text PDF
July 2014

Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.

Neurology 2014 Jul 6;83(2):192-4. Epub 2014 Jun 6.

From The Daroff-Dell'Osso Laboratory (A.S., M.M.S., J.B.J., M.F.W.), Louis Stokes Veterans Affairs Medical Center; University Hospitals (A.S.); Case Western Reserve University (A.S., J.B.J., M.F.W.); and the Mellen Center for Multiple Sclerosis Treatment and Research (J.A.C.), Neurological Institute, Cleveland Clinic, Cleveland, OH.

View Article and Find Full Text PDF
July 2014

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Neurology 2014 Jul 28;83(3):278-86. Epub 2014 May 28.

From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark; University College London Institute of Neurology (A.J.T.), UK; the Department of Neurology (J.S.W., J.A.L.), University of Texas Health Sciences Center, Houston; the Department of Neurology (L.J.B.), New York University Langone Medical Center, New York; the Division of Neurology (B. Banwell), The Children's Hospital of Philadelphia, PA; the Departments of Radiology and Nuclear Medicine (F.B.) and Neurology (C.H.P.), VU Medical Center, Amsterdam, the Netherlands; Research Programs Department (B. Bebo), National Multiple Sclerosis Society, New York, NY; the Department of Neurology (P.A.C.), The Johns Hopkins Hospital, Baltimore, MD; Fédération de Neurologie (M.C.), CHU Hôpital Purpan, Toulouse, France; the Department of Neurology (G.C.), Scientific Institute San Raffaele, University Vita-Salute San Raffaele, Milan, Italy; University of Ottawa and the Ottawa Hospital Research Institute (M.S.F.), Canada; the Department of Neurology (A.D.G.), University of Rochester Medical Center, NY; the Departments of Neurology, Radiology and Neuroscience (M.I.), Mount Sinai School of Medicine, New York, NY; the Department of Neurology (L.K.), University Hospital, Basel, Switzerland; the Department of Neurology (B.C.K.), Heinrich-Heine-University, Düsseldorf, Germany; the Department of Neurology (C.L.), Salpêtrière Hospital, UPMC, Paris, France; the Department of Neurology-Neuroimmunology (X.M.), Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain; the Division of

View Article and Find Full Text PDF
July 2014